17-OHP to the time of ultrasonographic measurement. To determine whether the patients were undertreated, we calculated the percentage of serum 17-OHP measurements >10 ng/mL relative to the total number of measurements during the follow-up period. To adjust the different number of measurements of each subject, we used the percentage in the analysis (number of measurements; mean±SD (min., max.), 23.6±6.4 (10, 32) ). We arbitrarily divided the 6-year follow-up period just before ultrasonographic measurement (time 0) into three 2-year intervals and calculated the average concentration of serum 17-OHP in each interval, -2 nd to 0 year-average concentration (-2-0YAC), -4 th to -2 nd year-average concentration (-4-2YAC) and -6 th to -4 th year-average concentration (-6-4YAC).
Color Doppler ultrasonography of the testis was performed by experienced pediatric radiologists. The high resolution ultrasound (LOGIQ 9, General Electric Company, Milwaukee, WS, USA or Acuson Sequoia 512, Siemens Medical Solutions USA, Mountain View, CA, USA) with 12-15 MHz linear probe was used in the examination. Low-echoic and hypervascular masses were identified as TARTs, which were larger than 0.1 cm. The maximal cross-sectional area and the volume of the TARTs were calculated using the formula for a prolate ellipse as follows:
Maximal cross-sectional area of TART (cm 2 ) = п × d1(cm) × d2(cm) ÷ 4 (п =3.14)
Volume of TART (cm 3 ) = п × d1(cm) × d2(cm) × d3(cm) ÷ 6 (п =3.14) where d1 is the largest diameter, d2 is the mediumsized diameter, and d3 is the smallest diameter.
When there were multiple masses, the largest one was selected for calculation.
Statistics
The data are presented as median and range (minimum, maximum). Statistical analyses were performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Differences between two subgroups classified according to the type of CAH and the existence of a TART were assessed by Mann-Whitney test and Fisher's exact test. Comparison among three 2-year interval average concentrations was analyzed by Friedman test. Spearman's rho was used to identify the associations between the maximal cross-sectional area of each TART and the continuous variables. In multiple regression analysis, the maximal cross-sectional area of a TART was transformed to the logaels, the adrenal tissue remnants become hyperplastic and eventually develop tumors. Thus, TARTs are also found in other diseases with high ACTH levels, such as Nelson's syndrome and Cushing's disease [11] , and the size of a TART is reduced by adequate suppression of ACTH secretion by treatment [12] . TARTs do not occur in patients with nonclassic or late-onset CAH, because ACTH level is not elevated enough [3] .
The reported prevalence of TARTs in patients with CAH varies between 0% and 94% [3, 6, 12] , depending on the age of the patients, type of CAH, method of detection, and target range of disease control [13] [14] . We performed this study to observe the prevalence of TARTs, measured by testicular ultrasonography, and to analyze its contributing factors, such as the degree of disease control, in postpubertal patients with CAH caused by 21-hydroxylase deficiency.
Materials and Methods

Patients
Forty-eight male patients, older than 10 years and followed up regularly through the outpatient clinic for the treatment of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency, were included. Prepubertal patients were excluded. Of the 48 patients, 36 (75.0%) had the salt-wasting (SW) type and 12 (25.0%) had the simple-virilizing (SV) type. They had a median age of 16.3 years (range 10.6-27.1). The study protocol was approved by the institutional ethics committee, and informed consent was obtained from patients and their parents.
Methods
We retrospectively reviewed the medical records and measured or calculated the height, weight, body mass index (BMI), and frequency, dose and type of medications at the time of ultrasonographic measurement. In general, most patients with CAH achieve a final adult height below their target height [15] . Therefore, the final adult height, expressed as a standard deviation score (SDS), was corrected for genetic potential (final adult height SDS minus mid-parental height SDS) in patients who reached their final height. Disease duration was calculated as time of diagnosis to the time of ultrasonographic measurement.
We defined the adequate control of CAH as a serum level of 17-hydroxyprogesterone (17-OHP) ≤10 ng/ mL [16] . We recorded the past random levels of serum rithmic value to make it parametric. Several factors, which were identified to be correlated with the size of a TART by the simple correlation analysis, were used as independent variables. P-values <0.05 were considered significant.
Results
Clinical characteristics of the patients
The median age of the patients at the time of ultrasonographic measurement was 16.7 years for those with the SW type and 12.7 years for those with the SV type. The median duration of disease was 15.6 and 6.2 years, respectively. The median age and disease duration showed differences between the SW and SV type (age, P=0.038; disease duration, P=0.001).
Of the 48 patients, 21 (42.9%) were treated with hydrocortisone, and 28 (57.1%) were treated with prednisolone. The median hydrocortisone-equivalent dose at the time of ultrasonographic measurement was 16.2 mg/m 2 /day, assuming that prednisolone is four times more potent than hydrocortisone. The BMI of total patients was 24.0 (17.8, 34.0) kg/m 2 . The corrected final adult height SDS of 40 patients was -1.8 (-4.9, 0.7).
The median percentage of undertreatment of the 48 patients was 82.4 %. The mean serum 17-OHP concentration was 74.2 ng/mL at -2-0YAC (n=48), 53.0 ng/mL at -4-2YAC (n=47), and 58.0 ng/mL at -6-4YAC (n=45) ( Table 1 ). The -2-0 YAC value was significantly higher than the others (P=0.010).
Testicular ultrasonography
TARTs were detected in 31 of 48 patients (64.6%), all of which were located adjacent to the mediastinum testis ( Fig. 1) . Bilateral TARTs were detected in 27 of 31 
(a) (B)
The age at the time of ultrasonographic measurement, disease duration, hydrocortisone-equivalent dose, undertreatment percentage, -2-0YAC, and -6-4YAC did not correlated significantly with the presence of a TART. However, the patients with a TART had a significantly lower corrected final adult height and higher BMI and -4-2YAC to compare with those without a TART (Table 3) . There were no significant differences among three 2-year interval average concentrations in patient with a TART (P=0.111).
Relationships between the maximal cross-sectional area of TARTs and indices of disease control
The maximal cross-sectional area of the TARTs was positively correlated to the age at the time of ultrasonopatients (87.1%) and each TART appeared mainly as a single mass. [13] , who reported a prevalence rate of 94% for patients older than 17 years. Several factors may explain why our results were different from those of other reports. First, we excluded prepubertal patients in our study. ACTH, angiotensin II (AII), and luteinizing hormone (LH) are known as trophic factors of TARTs, and LH receptors may exist in testicular adrenal rest tissue [3, 11] . Therefore, increased LH levels might promote the growth of a TART during puberty [11, 17] . In a study of 2-18-yearold patients, [17] TARTs were found in eight patients, six of whom were older than 10 years. In two of the six patients, TARTs had not been detected in testicular ultrasonography performed before the age of 10 years. (Fig. 2) .
After controlling for the type of CAH, hydrocortisone-equivalent dose and age at time of the ultrasonographic measurement, and -6-4 YAC in multiple regression analysis, the maximal cross-sectional area of the TARTs was associated with a high undertreatment percentage with a marginal statistical significance (Table 4) .
Discussion
Our results showed that the prevalence of TARTs was ACTH levels. However, if a large amount of adrenal tissue rests in the testis during the early embryonic period, a TART could grow under conditions of mildly elevated ACTH level or in response to other factors. Further efforts to find other trophic factors that can cause TART growth suggest a relationship between the growth of TARTs and CYP21A2 gene mutations [4, [13] [14] . In most cases, the activity of 21-hydroxylase depends on the type of mutation; very low enzyme activity is associated with a high prevalence of TARTs [14] . That is, when there is no 21-hydroxylase activity, ACTH level would be very high in the early embryonic period, and the chance of the hyperplastic adrenal tissue migrating along with the testis should increase [8, 13] . In the same context, the size of a TART can differ according to the type of CAH [18] . In our study, the prevalence and maximal cross-sectional area of TARTs were not significantly associated with the type of CAH, although there might be variable genotypes within a subtype, which we cannot test because of the lack of genetic studies. Both ACTH and AII have a strong trophic effect on adrenal tissue [3, 8] , and clinicians should consider the effect of AII in patients with the salt-wasting type of CAH. Because testicular adrenal rest tissue also produces steroid hormones [3] and a TART is a functional tissue like the adrenal cortex, the serum levels of androstenedione and 17-OHP may be elevated in patients with a TART [2, 8] . It is difficult to identify causal relationships between the elevated serum 17-OHP level and the existence of a TART in the cross-sectional study. We calculated the average serum 17-OHP level at 2-year intervals and anticipated that the -2-0YAC in patients with a TART might be the highest of the three 2-year intervals before ultrasonographic measurement. However, the average concentration did not differ significantly among three 2-year intervals in patients with a TART, although -2-0YAC was the highest in all patients. The correlation between -2-0YAC and the maximal TART cross-sectional area was also not significant. Another limitation of our study is that we could not measure serum concentrations of 17-OHP >125 ng/mL.
The TARTs usually exist bilaterally, which is different from the other malignancies of the testis [26] . The laterality is not observed in the testicular cancer, such as seminoma, Sertoli cell tumor, and Leydig cell tumor [27, 28] . Therefore, although the median maximal cross-sectional area of TART was larger in the right testis than in left testis in our study this might have no Second, the median percentage of undertreatment was 82.4% in our study, which is considerably higher than that in other reports [18] [19] . We considered the serum 17-OHP concentration greater than the upper target of 10 ng/mL to indicate undertreatment. The target range for serum 17-OHP level differs between review articles: 12 ng/mL [20] or 33.1 ng/mL [21] . The serum 17-OHP level also has a large diurnal variation and can change rapidly after administration of hydrocortisone [22] [23] [24] . Thus, a single measurement of serum 17-OHP concentration is not sufficient for evaluating the extent of disease control. For these reasons, it is possible that we overestimated the number of undertreated patients. And the number of examinations during follow-up period for each individual differed. But the undertreatment percentage serves as a cumulative indicator of the median follow-up of 12.9 years and reflects the chronic increase in plasma ACTH levels. Finally, the smallest cross-sectional area of a TART seen as low-echoic and hypervascular tissue on the ultrasound image was 0.03 cm 2 in our patients. This was smaller than the value in most other reports, which found that TARTs were detected when they were at least 2 mm [13, 17, 25] . For these reasons, the prevalence of TARTs in our study might be higher than expected.
Patients with a TART had a lower corrected final adult height, which indicates the clinical aspects of disease control, than those without a TART. The maximal cross-sectional area of a TART correlated with many factors but after controlling for these variables, the undertreatment percentage was shown to be the most contributing factor. The reason why the undertreatment percentage showed a marginal statistical significance in multiple regression analysis may be due to the multicollinearity, especially with -6-4YAC. When -6-4YAC was excluded, the undertreatment percentage was significantly correlated with the size of TART even after controlling for the type of CAH, hydrocortisoneequivalent dose and age at the time of ultrasonographic measurement, which we did not describe in the result. Therefore, long-term disease control is most important in the development of TARTs.
The correlation coefficients were not very high, indicating that other factors contribute to the growth of TARTs. Some believe that a TART can develop irrespective of disease control; [3, 11] Stikkelbroeck et al. [13] reported that TARTs were also detected in wellcontrolled patients. If adrenal tissue does not rest in the testis, TARTs would not develop even with high the time to begin and the intervals for TART screening. Claahsen-van der Grinten [31] proposed that screening for TARTs should begin at 8 years of age and should be repeated annually; however, this is usually only recommended when patients reach puberty [1, [32] [33] .
In conclusion, the prevalence of TARTs was 64.6% in postpubertal male patients with CAH caused by 21-hydroxylase deficiency. The occurrence and progression of TARTs might be associated with the degree of disease control. Our results suggest that strict disease control is mandatory and that regular examination with testicular ultrasonography should be performed in male patients regardless of the type of 21-hydroxylase deficiency.
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Generally, the prevalence of TARTs increases with age. One report [17] stated that TARTs were detected after a 1-or 2-year follow-up in patients who initially had no TART. Our result was similar in that the prevalence was >70% in patients older than 15 years and the patient's age might affect the size of TART. Therefore, screening for the existence of a TART should be mandatory in male patients. However, because TARTs exist mainly in the rete testis and a diameter >2 cm is palpable [3] , early detection by physical examination is difficult. Testicular enlargement detected by palpation can be mistaken for precocious puberty [29] . The presence of a TART is a known risk factor for infertility, which can be confirmed by blood or semen analysis [4, 13, [17] [18] 30] but changes may start in childhood [4] . Thus, imaging tools such as ultrasonography and magnetic resonance imaging (MRI) are recommended for screening [10, 31] . Ultrasonographic measurement is more accessible than MRI and has equal sensitivity in detecting a mass, although MRI has better contrast resolution than ultrasound imaging for measuring the size of mass and extent of disease [12] . Thus, ultrasonography may be best for routine periodic examinations and MRI for confirming a mass, especially if a fast-growing tumor is suspected [32] . There is no consensus about
